NCT06613360
A Study of CLN-978, a Subcutaneously Administered CD19-directed T Cell Engager, in Subjects With Systemic Lupus Erythematosus
Track this trial
Free. We email you which fields changed when ClinicalTrials.gov updates this record.
Record History
All 14 versions: 13 with changes below, 1 re-verified with no change. See every version on ClinicalTrials.gov ↗
- Minor Trial sites expanded: 20 → 24 locations
- Site contacts updated at 1 of 24 sites
- Notable Eligibility criteria expanded, about 31 words
- Study sites: 20 to 24
- Minor Trial sites expanded: 17 → 20 locationsv12
- Minor Study sites: 15 to 17v11
- Minor Study sites: 14 to 15v10
Show 7 earlier versionsHide 7 earlier versions
- Minor Study sites: 12 to 14v9
- Notable Eligibility criteria expanded, about 6 words
- Study sites: 11 to 12
- Minor Study sites: 9 to 11v7
- Minor Study sites: 3 to 9
- Start date changed from estimate of Jan 2025 to Jan 21, 2025
- Minor Study sites: 2 to 3
- Start date: Dec 2024 to Jan 2025
- Notable Trial status: Not Yet Recruiting to Recruiting
- Study sites: 0 to 2
- Start date: Nov 2024 to Dec 2024
- Minor Study title expanded, about 2 wordsv2
- Study First Submitted
- Notable: the plan changed
- Minor: routine updates
Endpoints
Primary
Safety and tolerability
Timeframe: 48 weeks
Secondary (3)
Pharmacokinetics
Immunogenicity
Pharmacodynamics-related biomarker
Arms and interventions
Part A Dose EscalationExperimental
Patients with SLE treated with CLN-978 in dose escalation cohorts
Part B Further Dose EvaluationExperimental
Further evaluation of CLN-978 treatment of patients with SLE
Drugs: CLN-978
Sites
24 sites in 9 countries
United States 12, France 3, Australia 2, Romania 2, Bulgaria 1, Georgia 1, Germany 1, Moldova 1, Spain 1